Free shipping on all orders over $ 500


Cat. No. M1822
PD98059 Structure

PD 98059

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 52  USD52 In stock
5mg USD 45  USD45 In stock
10mg USD 60  USD60 In stock
25mg USD 100  USD100 In stock
100mg USD 230  USD230 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase. MEK/ERK pathways are frequently activated in acute myelogenous leukemia, and this signal pathway's inhibitor has made it an interesting candidate for cancer chemotherapy. PD98059 inhibits cell growth and proliferation in acute myelogenous leukemia (AML) cell lines; causes G1 arrest by blocking p53-dependent p21 induction. PD98059 significantly arrests the G1 phase through up-regulation of cyclin-dependent kinase (Cdk) inhibitor, and produces morphological features of apoptosis in U937 cells, which were associated with poly(ADP-ribose)polymerase (PARP) cleavage and PLC-gamma1 degradation. PD98059 also decreased the Cdk-2, Cdk-4, cyclin D1, and cyclin E expression, and increased high levels of the mitotic inhibitors p16(INIa), p21(Waf1), and p27(Kip1). Also, Bcl-2's overexpression and a caspase-3 inhibitor z-DEVD-fmk significantly attenuated PD98059-induced apoptosis through the down-regulation of caspase-3 activity, but did not attenuate G1 phase arrest. Moreover, PD98059 down-regulated Akt phosphorylation and produced a synergy effect of apoptosis with LY294002 co-treatment. Other studies have shown that the expression of KAT2B protein in cells is significantly decreased after PD98059 inhibits ERK signaling pathway, suggesting that 17β-E 2 can increase KAT2B protein expression by activating ERK signaling pathway, thus enhancing ER activity and enhancing positive feedback of estrogen effect.

Product Citations
Customer Product Validations & Biological Datas
Source Experimental Eye Research (2018). Figure 3. PD98059 (Abmole Bioscience, Houston, TX, USA)
Method Western blot
Cell Lines ONH astrocytes
Concentrations 25 μM
Incubation Time 1 h
Results PD98059 did not significantly reduce the level of p-S6 kinase phosphorylation, but LY294002 showed a robust blockade of its phosphorylation.
Source PLoS One (2015). Figure 3. PD98059
Method Western blot
Cell Lines The rats
Concentrations 2.5 mcg/5 mcl
Incubation Time 16 h
Results The increased level of ERK1/2 (44/42kDa) in CCI-exposed rats was not observed in group which received repeated administration PD98059
Cell Experiment
Cell lines C-33 and C-81 cells
Preparation method Treatment with chemotherapeutic agents.
Cells were seeded in 6-well culture plates in regular culture medium at a density of 2.5*105 and 1*105 cells/well for C-33 and C-81 cells, respectively, for 2 days and then fed with SR medium, i.e., PR-free RPMI-1640 medium containing 5% heat-inactivated CS-FBS, 1% glutamine and 0.5% gentamicin. Two days after steroid starvation, one set of attached cells was harvested and counted as day 0. The remaining cells were fed with fresh SR medium and treated with PD98059, U0126, vinorelbine, docetaxel or various combinations in which the dosage of each reagent was specified. Control cells were maintained in SR medium and received solvent alone without chemotherapeutic agents. Fresh SR medium with or without chemotherapeutic agents was added every 3 days. Treatment was continued for 3 or 6 days, as described in each figure legend. To quantify the inhibition of cell growth, attached cells were trypsinized and the cells counted with a Coulter counter. The number of cells in control sets that received solvent alone was designated as 100% for comparison. All experiments were done in triplicate and repeated at least twice.
Concentrations 0~10 μM
Incubation time 3 or 6 days
Animal Experiment
Animal models acute lung injury in mice
Formulation DMSO, then diluted with saline
Dosages 10mg/kg
Administration i. p.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 267.28
Formula C16H13NO3
CAS Number 167869-21-8
Purity 99.83%
Solubility DMSO 15 mg/mL
Storage -20°C, dry, sealed, protect from light

[1] Di Paola R, et al. Int J Immunopathol Pharmacol. Effect of PD98059, a selective MAPK3/MAPK1 inhibitor, on acute lung injury in mice.

[2] Dokladda K, et al. FEBS Lett. PD98059 and U0126 activate AMP-activated protein kinase by increasing the cellular AMP:ATP ratio and not via inhibition of the MAP kinase pathway.

[3] Zelivianski S, et al. Int J Cancer. ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells.

[4] Hur E, et al. Mol Pharmacol. Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha.

Related MEK Products

Zapnometinib (PD0184264), an active metabolite of CI-1040, is an MEK inhibitor with an IC50 value of 5.7 nM. Zapnometinib has antiviral and antibacterial activity against influenza viruses.

GW284543 (UNC10225170)

GW284543 (UNC10225170) is a selective MEK5 inhibitor, which reduces pERK5 and decreases endogenous MYC protein.

RO5126766 (VS-6766)

RO5126766 (CH5126766, VS 6766) is a first-in-class dual MEK/RAF inhibitor with IC50 values of 8.2 nM, 19 nM, 56 nM and 160 nM for BRAF V600E, BRAF, CRAF and MEK1, respectively.


trans-Zeatin is a plant cytokinin, which plays an important role in cell growth, differentiation, and division.


RO4987655 is an orally active and highly selective MEK inhibitor with an IC50 of 5.2 nM.

Abmole Inhibitor Catalog 2017

Keywords: PD98059, PD 98059 supplier, MEK, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.